Last reviewed · How we verify
Etodalac, Etoricoxib and Dexamethasone — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Etodalac, Etoricoxib and Dexamethasone (Etodalac, Etoricoxib and Dexamethasone) — Tel-Aviv Sourasky Medical Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Etodalac, Etoricoxib and Dexamethasone TARGET | Etodalac, Etoricoxib and Dexamethasone | Tel-Aviv Sourasky Medical Center | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Etodalac, Etoricoxib and Dexamethasone CI watch — RSS
- Etodalac, Etoricoxib and Dexamethasone CI watch — Atom
- Etodalac, Etoricoxib and Dexamethasone CI watch — JSON
- Etodalac, Etoricoxib and Dexamethasone alone — RSS
Cite this brief
Drug Landscape (2026). Etodalac, Etoricoxib and Dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/etodalac-etoricoxib-and-dexamethasone. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab